Analysts Rally Behind Waystar: Predict Robust Growth and Market Share Gains Following Competitor Setback
Analysts Rally Behind Waystar: Predict Robust Growth and Market Share Gains Following Competitor Setback
BofA Securities analyst Allen Lutz initiated coverage on Waystar Holding Corp. (NASDAQ:WAY) with a Buy rating and price forecast of $27.
BofA Securities分析师Allen Lutz发表评论，将Waystar Holding Corp. (NASDAQ:WAY)评级为“买入”，目标价为27美元。
According to Lutz, Waystar is well positioned for 10% revenue growth supported by steady end-market demand and recent competitive changes.
根据Lutz的说法，Waystar因市场需求稳定和近期竞争变化的支持而处于良好位置，将实现10%的营收增长。
In addition, the cybersecurity attack on competitor Change Healthcare could drive Waystar's market share gains.
此外，Change Healthcare的网络安全攻击可能会推动Waystar的市场份额增长。
In response to the Change disruption in February, Waystar launched a program for impacted providers to expedite access to its platform within 2-3 days of contract execution.
针对2月份发生的Change干扰，Waystar推出了一个计划，以便受影响的提供商在合同签订后2-3天内快速访问其平台。
The company initially added 30K provider customers and could add more over the next few quarters, the analyst adds.
分析师补充道，公司最初增加了3万个服务商客户，未来几个季度可能会增加更多客户。
Waystar operates in a $15 billion market, with stable ~40% margins over the next three years. Precisely, the company has a solid opportunity to expand its existing relationships with 18 of the top 22 hospitals and potential changes in the competitive environment can support further growth.
Waystar在150亿美元的市场中运营，在未来三年内有着稳定的40%利润率。公司与前22家医院中的18家已经建立了很好的关系，未来的竞争环境变化有助于进一步增长。
Over time, Lutz projects a structural shift in health systems, reducing dependence on Change by diversifying with independent vendors to guard against future cyber breaches. The analyst projects FY24 EPS of $0.20.
随着时间的推移，Lutz预计卫生系统将出现结构性转变，通过与独立供应商组合减少对Change的依赖，以防止未来的网络安全漏洞。分析师预测FY24每股收益为0.20美元。
Goldman Sachs analyst Adam Hotchkiss initiated coverage on Waystar with a Buy rating and a $32 price forecast.
高盛分析师Adam Hotchkiss将Waystar评级为“买入”，目标价为32美元。
Per Hotchkiss, Waystar's comprehensive technology platform, addressing multiple points across the healthcare revenue cycle, is unique within a market dominated by point-solution technology vendors, manual processes, and healthcare IT services businesses.
Hotchkiss指出，Waystar的全面技术平台，在卫生保健收入周期的多个关键点进行了解决，这在由点解决方案技术供应商、手动流程和卫生保健IT服务企业主导的市场中是独一无二的。
The analyst adds that Waystar's deliberate combination of assets drives a more compelling sale to and partnership with larger hospitals and health systems. The analyst projects FY24 EPS of $0.21.
分析师补充道，Waystar的资产有意地结合起来，向大型医院和卫生系统提出了更具吸引力的销售和合作。分析师预测FY24每股收益为0.21美元。
William Blair analyst Ryan Daniels initiates coverage on Waystar Holding with an Outperform rating.
William Blair分析师Ryan Daniels将Waystar Holding评级为“跑赢大盘”（Outperform）。
For fiscal 2024, the analyst projects total revenue of $885 million, adjusted EBITDA of $351 million, and adjusted earnings per share of $0.19.
对于2024财年，分析师预计总收入为8.85亿美元，调整后的EBITDA为3.51亿美元，调整后的每股收益为0.19美元。
For fiscal 2025, Daniels projects revenue of $971 million, adjusted EBITDA of $380 million, and adjusted earnings per share of $0.69.
对于2025财年，Daniels预计收入为9.71亿美元，调整后的EBITDA为3.8亿美元，调整后的每股收益为0.69美元。
Price Action: WAY shares are trading higher by 0.46% to $21.61 at last check Tuesday.
股票价格行情：在上周二最后一次检查时，WAY股票价格上涨了0.46%，达到21.61美元。
Image via Dall-E 3
图像通过Dall-E 3